Anixa Biosciences, Inc.

NasdaqCM:ANIX Aktierapport

Börsvärde: US$104.1m

Anixa Biosciences Förvaltning

Förvaltning kriterier kontrolleras 3/4

Anixa Biosciences VD är Amit Kumar, utsedd i Jul 2017, har en mandatperiod på 13.67 år. totala årliga ersättningen är $ 2.55M, bestående av 32% lön 68% bonusar, inklusive företagsaktier och optioner. äger direkt 1.85% av företagets aktier, värda $ 1.93M. Den genomsnittliga mandatperioden för ledningsgruppen och styrelsen är 9 år respektive 7.8 år.

Viktig information

Amit Kumar

Verkställande direktör

US$2.5m

Total ersättning

VD-lön i procent32.01%
Anställning som VD9yrs
Ägande av VD1.9%
Ledningens genomsnittliga anställningstid9yrs
Styrelsens genomsnittliga mandatperiod7.8yrs

Senaste uppdateringar av ledningen

Recent updates

Analysartikel • Mar 25

We're Not Very Worried About Anixa Biosciences' (NASDAQ:ANIX) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysartikel • Dec 19

Are Investors Undervaluing Anixa Biosciences, Inc. (NASDAQ:ANIX) By 40%?

Key Insights The projected fair value for Anixa Biosciences is US$4.21 based on 2 Stage Free Cash Flow to Equity Anixa...
Analysartikel • Sep 12

We're Not Very Worried About Anixa Biosciences' (NASDAQ:ANIX) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Analysartikel • May 23

We're Hopeful That Anixa Biosciences (NASDAQ:ANIX) Will Use Its Cash Wisely

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Analysartikel • Jan 19

We're Not Worried About Anixa Biosciences' (NASDAQ:ANIX) Cash Burn

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Analysartikel • Oct 06

We Think Anixa Biosciences (NASDAQ:ANIX) Can Easily Afford To Drive Business Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Analysartikel • Apr 27

Is There An Opportunity With Anixa Biosciences, Inc.'s (NASDAQ:ANIX) 41% Undervaluation?

Key Insights The projected fair value for Anixa Biosciences is US$7.24 based on 2 Stage Free Cash Flow to Equity Anixa...
Analysartikel • Jan 13

Are Investors Undervaluing Anixa Biosciences, Inc. (NASDAQ:ANIX) By 36%?

Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Anixa Biosciences...
Analysartikel • Sep 26

We're Interested To See How Anixa Biosciences (NASDAQ:ANIX) Uses Its Cash Hoard To Grow

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Seeking Alpha • Aug 15

Anixa adds 11% after dosing initiation in CAR-T ovarian cancer trial

The shares of clinical-stage biotech Anixa Biosciences (NASDAQ:ANIX) jumped ~11% to reach the highest level since November on the announcement that the first patient received its chimeric antigen receptor T-cell (CAR-T) therapy in a Phase 1 clinical trial for ovarian cancer.   The dose escalation study conducted with its partner Moffitt Cancer Center is designed to assess the early efficacy data, safety and maximum tolerated dose of the follicle-stimulating hormone receptor T-cells. The trial is expected to enroll up to 48 patients at the Moffitt Cancer Center. Anixa’s (ANIX) CAR-T approach used in the study is known as chimeric endocrine receptor T-cell (CER-T) therapy. It differs from traditional CAR-T drugs in that it specifically targets the follicle-stimulating hormone receptor (FSHR) which, according to research, is exclusively located in ovarian cells of healthy adult women. In March, Anixa (ANIX) announced initial plans to conduct the trial.
Seeking Alpha • Jul 21

Anixa to get additional US patent linked to breast cancer vaccine technology

Anixa Biosciences (NASDAQ:ANIX) said the U.S. Patent and Trademark Office (USPTO) issued a Notice of Allowance for a new patent related to the company's breast cancer vaccine technology. The company said the technology has been exclusively licensed from and is being developed in partnership with Cleveland Clinic. The patent is titled 'Breast Cancer Vaccine' and the lead inventor is Vincent Tuohy of the Department of Inflammation and Immunity at Cleveland Clinic's Lerner Research Institute. "This breast cancer vaccine has the potential to prevent Triple Negative Breast Cancer ("TNBC"), the deadliest form of breast cancer, and perhaps other forms of breast cancer that express alpha-lactalbumin," said Anixa Chairman and CEO Amit Kumar.
Analysartikel • Jun 13

Anixa Biosciences (NASDAQ:ANIX) Is In A Good Position To Deliver On Growth Plans

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Seeking Alpha • May 11

Anixa: Making Sense Of A Bullish Move Up In Bearish Biotech Times

Anixa Biosciences has different very interesting programs ongoing, one of which is a breast cancer vaccine trial with a first partial readout at ASCO in the beginning of June. While the biotech sector has been suffering large losses over the past month, Anixa Biosciences shares have moved up remarkably. Trial enrollment for the vaccine trial was fast, and the company seems optimistic about the near-term future of the company. The market is huge, and if the trial is successful, chances are we are seeing the beginning of a huge spike in share price. 2022 will, in any case, be the year for Anixa, with other programs ongoing as well.
Analysartikel • Feb 24

We're Interested To See How Anixa Biosciences (NASDAQ:ANIX) Uses Its Cash Hoard To Grow

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysartikel • Oct 28

Companies Like Anixa Biosciences (NASDAQ:ANIX) Can Afford To Invest In Growth

We can readily understand why investors are attracted to unprofitable companies. By way of example, Anixa Biosciences...
Seeking Alpha • Sep 23

Our First Look At Anixa Biosciences

Today, we take an in-depth look at Anixa Biosciences, a small developmental firm on the west coast. The company's pipeline has multiple 'shots on goal' including one candidate that has shown some early analytical potential promise against the Covid-19 Delta variant. A full analysis is provided in the paragraphs below.
Analysartikel • Jun 12

Here's Why We're Not At All Concerned With Anixa Biosciences' (NASDAQ:ANIX) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

Analys av ersättningar till VD

Hur har Amit Kumar:s ersättning förändrats jämfört med Anixa Biosciences:s resultat?
DatumTotal ersättningLönFöretagets resultat
Apr 30 2026n/an/a

-US$10m

Jan 31 2026n/an/a

-US$10m

Oct 31 2025US$3mUS$815k

-US$11m

Jul 31 2025n/an/a

-US$11m

Apr 30 2025n/an/a

-US$12m

Jan 31 2025n/an/a

-US$12m

Oct 31 2024US$3mUS$785k

-US$13m

Jul 31 2024n/an/a

-US$12m

Apr 30 2024n/an/a

-US$12m

Jan 31 2024n/an/a

-US$11m

Oct 31 2023US$4mUS$720k

-US$10m

Jul 31 2023n/an/a

-US$11m

Apr 30 2023n/an/a

-US$11m

Jan 31 2023n/an/a

-US$12m

Oct 31 2022US$2mUS$631k

-US$14m

Jul 31 2022n/an/a

-US$14m

Apr 30 2022n/an/a

-US$16m

Jan 31 2022n/an/a

-US$15m

Oct 31 2021US$11mUS$573k

-US$13m

Jul 31 2021n/an/a

-US$11m

Apr 30 2021n/an/a

-US$9m

Jan 31 2021n/an/a

-US$10m

Oct 31 2020US$2mUS$522k

-US$10m

Jul 31 2020n/an/a

-US$10m

Apr 30 2020n/an/a

-US$9m

Jan 31 2020n/an/a

-US$9m

Oct 31 2019US$665kUS$476k

-US$12m

Ersättning vs marknad: Amit s total kompensation ($USD 2.55M ) är över genomsnittet för företag av liknande storlek på US marknaden ($USD 658.93K ).

Ersättning vs inkomst: Ersättningen från Amit har varit i linje med företagets resultat under det senaste året.

VD OCH KONCERNCHEF

Amit Kumar (62 yo)

9yrs
Anställning
US$2,546,684
Kompensation

Dr. Amit Kumar, Ph.D. was a Director at Ascent Solar Technologies, Inc. since June 2007 until September 16, 2022 and had been its Independent Chairman of the Board since January 2011 until September 16, 20...

Ledningsgrupp

NamnPositionAnställningKompensationÄgarskap
Amit Kumar
CEO, Chairman & Co-Chair of CBAB9yrsUS$2.55m1.85%
$ 1.9m
Michael Catelani
President9.7yrsUS$1.30m0.13%
$ 136.2k
Pamela Garzone
Chief Development Officer & Chair Breast Cancer Clinical Advisory Board4.8yrsinga uppgifteringa uppgifter
9.0yrs
Genomsnittlig anställningstid
62yo
Genomsnittlig ålder

Erfaren ledning: ANIX s ledningsgrupp är erfaren och erfaren ( 9 års genomsnittlig anställning).

Styrelseledamöter

NamnPositionAnställningKompensationÄgarskap
Amit Kumar
CEO, Chairman & Co-Chair of CBAB13.7yrsUS$2.55m1.85%
$ 1.9m
Pamela Garzone
Chief Development Officer & Chair Breast Cancer Clinical Advisory Board3.4yrsinga uppgifteringa uppgifter
Lewis Titterton
Lead Independent Director9yrsUS$134.63k2.86%
$ 3.0m
H. Shepard
Member of Scientific Advisory Boardno datainga uppgifteringa uppgifter
Linda Kelley
Member of Scientific Advisory Board7.8yrsinga uppgifteringa uppgifter
Ian Frazer
Member of Scientific Advisory Board6.8yrsinga uppgifteringa uppgifter
G. Budd
Member of Breast Cancer Clinical Advisory Board3.4yrsinga uppgifteringa uppgifter
Arnold Baskies
Member of SAB & Breast Cancer Clinical Advisory Board7.8yrsUS$134.63k0.40%
$ 413.1k
Marco Davila
Member of Scientific Advisory Board7.8yrsinga uppgifteringa uppgifter
Jose Conejo-Garcia
Member of Scientific Advisory Board7.8yrsinga uppgifteringa uppgifter
Daniel Abate-Daga
Member of Scientific Advisory Board7.8yrsinga uppgifteringa uppgifter
Emily Gottschalk
Independent Director6.8yrsUS$134.63k0.13%
$ 139.7k
7.8yrs
Genomsnittlig anställningstid
73yo
Genomsnittlig ålder

Erfaren styrelse: ANIX s styrelse anses vara erfaren ( 7.8 års genomsnittlig mandatperiod).

Företagsanalys och finansiella data Status

UppgifterSenast uppdaterad (UTC-tid)
Analys av företag2026/07/13 17:53
Aktiekurs vid dagens slut2026/07/10 00:00
Intäkter2026/04/30
Årlig intjäning2025/10/31

Datakällor

Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.

PaketUppgifterTidsramExempel US-källa
Företagets finansiella ställning10 år
  • Resultaträkning
  • Kassaflödesanalys
  • Balansräkning
Analytikernas konsensusuppskattningar+3 år
  • Prognos för finansiella poster
  • Analytikernas prismål
Marknadspriser30 år
  • Aktiekurser
  • Utdelningar, splittar och åtgärder
Ägarskap10 år
  • Största aktieägare
  • Insiderhandel
Förvaltning10 år
  • Ledningsgrupp
  • Styrelse och verkställande direktörer
Viktiga utvecklingstendenser10 år
  • Företagsmeddelanden

* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.

Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.

Analysmodell och snöflinga

Detaljer om analysmodellen som används för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och handledningar på Youtube.

Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.

Industri- och sektormått

Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.

Källor för analytiker

Anixa Biosciences, Inc. bevakas av 7 analytiker. 4 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.

AnalytikerInstitution
Andrew D'SilvaB. Riley Securities, Inc.
Jason KolbertD. Boral Capital LLC.
Patrick McCannD. Boral Capital LLC.